Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 05 May 2016

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Adefovir-related nephrotoxicity by adefovir dose-reduction in HBV

A study in the latest issue of Alimentary Pharmacology & Therapeutics investigates resolution of adefovir-related nephrotoxicity by adefovir dose-reduction in patients with chronic hepatitis B.

News image

Chronic hepatitis B patients treated with adefovir were followed up to evaluate nephrotoxicity and its outcome.

Dr Hartono and colleagues assessed the incidence of renal dysfunction during adefovir therapy in Asian patients and factors associated with it.

The team evaluated strategies to improve adefovir-related renal dysfunction, and their impact on viral suppression.

The researchers evaluated chronic hepatitis B clinic patients from a tertiary hospital on adefovir treatment.

The team extracted clinical and laboratory parameters from the hospital electronic clinical database in an observational study design.

Patients were excluded if they had liver/renal transplant, baseline renal impairment or were on dialysis.

The team of doctors defined adefovir-related renal dysfunction as adefovir-related abnormal serum creatinine as 125 μmol/L, 90 μmol/L for adefovir-related abnormal GFR 60 mL/min, and adefovir-related increased serum creatinine as 0.5 mg/dL, without other known causes of nephrotoxicity.

A total of 271 out of 383 adefovir-treated patients were suitable for analysis, and 33 patients developed abnormal serum creatinine.

Adefovir-related abnormal serum creatinine was 34%
Alimentary Pharmacology & Therapeutics

The research team found that cumulative increase in proportion of patients with adefovir-related abnormal serum creatinine was 34% and adefovir-related abnormal 60 mL/min was 38% by 6 years, while serum creatinine increase 0.5 mg/dL was 22% by 5 years.

Using multivariate analysis, the only independent baseline predictor of adefovir-related abnormal serum creatinine was adefovir-related abnormal 76.1 mL/min.

The team of doctors noted that patients who had adefovir-related abnormal serum creatinine had similar levels of viral suppression to those who did not have adefovir-related abnormal serum creatinine.

Those who had adefovir-related abnormal serum creatinine either continued adefovir, switched therapy or had adefovir dose reduction.

The researchers reported that adefovir-related abnormal serum creatinine resolved and adefovir-related abnormal normalised in almost all patients after either switching therapy or reducing adefovir dose, with no difference between the two strategies.

Those with adefovir dose reduction had no significant increase in HBV DNA.

Dr Hartono and his team commented, "Adefovir-related renal dysfunction occurred in a significant number of adefovir-treated patients, but reduction of the dose led to renal improvement without compromising treatment efficacy."

Aliment Pharmacol Ther 2013
04 March 2013

Go to top of page Email this page Email this page to a colleague

 05 May 2016 
Chemoradiotherapy vs chemotherapy for pancreatic cancer
 05 May 2016 
Genetics in early-early-onset IBD
 05 May 2016 
Reductions in quality of screening colonoscopies
 04 May 2016 
Anti-TNF therapy for IBD
 04 May 2016 
Bismuth and H. pylori eradication
 04 May 2016 
Chromoendoscopy vs colonoscopy for dysplasia in colitis
 03 May 2016 
Surgery vs medical therapy for GERD
 03 May 2016 
Vedolizumab for IBD
 03 May 2016 
PPIs and gut microbiota
 02 May 2016 
Resection of colorectal polyps
 02 May 2016 
Mycophenolate mofetil as first-line treatment of autoimmune hepatitis
 02 May 2016 
Genetic variant that increase NAFLD risk
 29 April 2016 
Simvastatins and survival in cirrhosis
 29 April 2016 
Crohn's disease associated genes
 29 April 2016 
HCV infection in Baby Boomers with Medicare
 28 April 2016 
Diarrheal diseases in children
 28 April 2016 
Racial disparities in survival from colon cancer
 28 April 2016 
Birth outcomes in women with IBD receiving assisted reproduction
 27 April 2016 
Dust mite and human GI tract
 27 April 2016 
Celiac disease in adults
 27 April 2016 
Ultra-short celiac disease
 26 April 2016 
Guidelines for nutrition therapy in hospitalized patients
 26 April 2016 
Polyp detection during colonoscopy
 26 April 2016 
IBS and microscopic colitis
 25 April 2016 
Estrogen deficiency and fibrosis risk in women with NAFLD
 25 April 2016 
Acceptance of Liver transplant center organ offers
 25 April 2016 
Abrupt interruption of beta-blockers in cirrhosis 
 22 April 2016 
Novel method to regenerate the esophagus
 22 April 2016 
Relapse after antiviral treatment in Hep B
 22 April 2016 
Microscopic colitis with NSAIDs and PPIs
 11 April 2016 
Infliximab vs adalimumab in ulcerative colitis
 11 April 2016 
H. pylori in treatment-naïve children
 11 April 2016 
Admissions times and outcomes for ERCP cholangitis
 08 April 2016 
Endoscopic treatment of Crohn's strictures
 08 April 2016 
Nutrition therapy in the hospitalized patient
 08 April 2016 
H.pylori effects on pediatric gastric mucosa
 07 April 2016 
CVD changes after TIPSS
 07 April 2016 
Transanal mesorectal resection for rectal cancer
 07 April 2016 
HBV during immunosuppressive therapies
 06 April 2016 
Adherence to colorectal cancer screening strategies
 06 April 2016 
Duodenal bulb biopsies in childhood celiac disease diagnosis
 06 April 2016 
Lymph node metastasis in early gastric cancer
 05 April 2016 
Colorectal cancer risk with serrated polyps
 05 April 2016 
IBS in the US military
 05 April 2016 
Changes in blood flow in cirrhosis
 04 April 2016 
Noninvasive diagnosis of celiac disease
 04 April 2016 
Metallic vs plastic stents for benign biliary strictures
 04 April 2016 
Adherence to quality indicators improves clinical outcomes in ascites
 01 April 2016 
Colorectal cancer risk with non-malignant colonoscopy findings
 01 April 2016 
Intensive enteral nutrition and severe alcoholic hepatitis
 01 April 2016 
Prognosis after colorectal cancer resection with peritoneal metastasis
 31 March 2016 
Management of Barrett’s esophagus
 31 March 2016 
Anesthesia services during colonoscopy
 31 March 2016 
Alcohol and glucose tolerance in NAFLD
 30 March 2016 
Depression and symptoms in IBS
 30 March 2016 
Electronic learning system for colon capsule endoscopy
 30 March 2016 
Gastric cancer screening
 29 March 2016 
Statins and survival in esophageal cancer
 29 March 2016 
Infant feeding practices and celiac disease
 25 March 2016 
Medical therapy and neoplasia regression in familial adenomatous polyposis

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2016 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us